OncoVee™-mini-patient-derived xenograft guided adjuvant chemotherapy treatment for resectable gastric cancer

Table 2 Patients’ demographic and tumor characteristics, n (%)

Characteristics	All (n = 36)	MiniPDX group (n = 16)	Experimental treatment group (n = 20)	P value
Age, years, median (range)	58 (42-79)	55 (42-66)	60 (47-79)	0.438
Age, group				0.813
≤ 60 years	24 (66.67)	11 (68.75)	13 (65.00)
> 60 years	12 (33.33)	5 (31.25)	7 (35.00)
Gender				0.593
Male	22 (61.11)	9 (56.25)	13 (65.00)
Female	14 (38.89)	7 (43.75)	7 (35.00)
ECOG PS
0-1	36 (100)	16 (100)	20 (100)
2	0 (0)	0 (0)	0 (0)
T-stage of primary tumor1				0.556
pT1	10 (27.78)	3 (18.75)	7 (35.00)
pT2	8 (22.22)	3 (18.75)	5 (25.00)
pT3	15 (41.67)	8 (50.00)	7 (35.00)
pT4	3 (8.33)	2 (12.50)	1 (5.00)
N-stage of primary tumor1				0.400
N0	19 (52.78)	6 (37.50)	13 (65.00)
N1	6 (16.67)	4 (25.00)	2 (10.00)
N2	2 (5.56)	1 (6.25)	1 (5.00)
N3	9 (25.00)	5 (31.25)	4 (20.00)
M-stage1
M0	36 (100)	16 (100)	20 (100)
M1	0 (0)	0 (0)	0 (0)
Stage of AJCC1				0.095
I	16 (44.44)	4 (25.00)	12 (60.00)
II	9 (25.00)	6 (37.50)	3 (15.00)
III	11 (30.56)	6 (37.50)	5 (25.00)

¹Tumor stage was defined according to the American Joint Committee on Cancer tumor-node-metastasis staging system (8^th edition).

MiniPDX: Mini patient-derived xenograft; ECOG PS: Eastern Cooperative Oncology Group Performance Status; AJCC: American Joint Committee on Cancer.